多斯塔利單抗
 | 此條目可參照英語維基百科相應條目來擴充。 (2025年2月7日) |
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | 程式性細胞死亡蛋白-1 (PDCD1) |
| 臨床資料 | |
| 商品名 | Jemperli |
| 其他名稱 | TSR-042, WBP-285, dostarlimab-gxly |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a621030 |
| 核准狀況 | |
| 懷孕分級 | |
| 給藥途徑 | 靜脈注射 |
| 藥物類別 | 化學療法 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 | |
| 識別資訊 | |
| CAS號 | 2022215-59-2 |
| PubChem SID | |
| DrugBank | |
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6420H9832N1690O2014S44 |
| 摩爾質量 | 144,325.73 g·mol−1 |
多斯塔利單抗（INN：dostarlimab）是治療某些實質固態瘤（如：子宮內膜癌）的藥物[10]。它用於治療具有DNA錯配修復缺陷（MisMatch Repair deficiency，MMRd 或 dMMR）特性的復發性或晚期癌症[10]。接受治療的患者中 44% 有效[11]。此藥物是以靜脈緩慢注射[11]。
常見的副作用包括疲倦、噁心、腹瀉和貧血[10]。其他副作用包括可能關節痛、瘙癢、皮疹、發燒和甲狀腺功能低下症[11]。嚴重的副作用包括可能因免疫功能障礙而引起的肺炎、結腸炎和肝炎[10]。懷孕期使用可能對嬰兒有害[10]。它是一種單株抗體，可阻斷程式性細胞死亡蛋白-1（PD-1），進一步使免疫系統殺死癌細胞[10] [11]。
多斯塔利單抗於 2021 年在美國和歐洲獲批用於醫療用途[10] [11]。
參考
[編輯]- ^ 1.0 1.1 Jemperli APMDS. Therapeutic Goods Administration (TGA). 2 March 2022 [5 March 2022]. （原始內容存檔於19 March 2022）.
- ^ Updates to the Prescribing Medicines in Pregnancy database. Therapeutic Goods Administration (TGA). 21 December 2022 [2 January 2023]. （原始內容存檔於3 April 2022）.
- ^ Notice: Multiple Additions to the Prescription Drug List (PDL) [2022-01-24]. Health Canada. 24 January 2022 [28 May 2022]. （原始內容存檔於29 May 2022）.
- ^ Summary Basis of Decision (SBD) for Jemperli. Health Canada. 23 October 2014 [29 May 2022]. （原始內容存檔於29 May 2022）.
- ^ Jemperli- dostarlimab injection. DailyMed. [28 April 2021]. （原始內容存檔於1 March 2022）.
- ^ FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer. U.S. Food and Drug Administration (FDA) (新聞稿). 22 April 2021 [22 April 2021]. （原始內容存檔於22 April 2021）.
本文含有此來源中屬於公有領域的內容。
- ^ FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer. U.S. Food and Drug Administration (FDA). 9 February 2023 [10 February 2023]. （原始內容存檔於10 February 2023）. 本文含有此來源中屬於公有領域的內容。
- ^ Jemperli EPAR. European Medicines Agency (EMA). 24 February 2021 [16 July 2021]. （原始內容存檔於14 May 2022）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Jemperli Product information. Union Register of medicinal products. [3 March 2023]. （原始內容存檔於5 March 2023）.
- ^ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 Jemperli- dostarlimab injection. DailyMed. [28 April 2021]. （原始內容存檔於1 March 2022）.
- ^ 11.0 11.1 11.2 11.3 11.4 Jemperli EPAR. European Medicines Agency (EMA). 24 February 2021 [16 July 2021]. （原始內容存檔於14 May 2022）.
延伸閱讀
[編輯]- Ali E, Ellahi A, Adil M, Shaikh A, Huda Z. Jemperli (Dostarlimab-gxly): An unprecedented cancer trial. Annals of Medicine and Surgery. July 2022, 79: 104047. PMC 9289402
. PMID 35860105. doi:10.1016/j.amsu.2022.104047.
外部連結
[編輯]- Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. Technology appraisal guidance (Reference number:TA779). NICE. 16 March 2022 [2025-01-12]. （原始內容存檔於2025-01-14）.1 Recommendations | Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | Guidance | NICE （頁面存檔備份，存於互聯網檔案館）
- Clinical trial number NCT02715284 for "Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET)" at ClinicalTrials.gov
